Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;18(5):1243-1252.
doi: 10.1007/s12265-025-10652-9. Epub 2025 Jul 21.

The Diagnostic Significance of Circulating Eicosanoid in Patients with Hypertrophic Cardiomyopathy

Yue Zhang  1 , Xinyu Liu  1 , Zhongze Zhang  1 , Weiyan Sun  1 , Wenjing Yue  1 , Le Liu  1 , Yi Zhu  1 , Xu Zhang  2 , Hong Wang  3
Affiliations

The Diagnostic Significance of Circulating Eicosanoid in Patients with Hypertrophic Cardiomyopathy

Yue Zhang et al. J Cardiovasc Transl Res. 2025 Oct.

Abstract

Hypertrophic cardiomyopathy (HCM) is one of the most prevalent hereditary cardiovascular diseases. Eicosanoids are known to play a significant role in cardiovascular diseases and serve as biomarkers. In this study, plasma eicosanoids were profiled by LC-MS in a cohort of 78 healthy individuals and 73 patients diagnosed with HCM. Our findings reveal HCM patients exhibit downregulation of various eicosanoids, including AA, 5,6-DHET, 12-HETE, LXA4, EPA, etc. Notably, the combined predictive model incorporating 12-HETE and EPA demonstrates significant diagnostic value for HCM. Additionally, ten closely related metabolites showed significant positive correlations within the metabolic network graph. Eicosanoids such as 17,18-EEQ, LXA4, and 13-oxo-ODE exhibit significant negative correlations with plasma concentrations of hs-CRP and NT-proBNP in patients. Alterations in eicosanoid metabolism may be implicated in the pathophysiological processes underlying HCM.

Keywords: Biomarkers; Eicosanoids; Hypertrophic cardiomyopathy; Metabolomics.

PubMed Disclaimer

Conflict of interest statement

Declarations. Human Subjects/Informed Consent: The human studies were performed with the Huazhong University of Science and Technology Institutional Review Board Approval (TJ-C20181001) and abiding by the Declaration of Helsinki principles. Written informed consents were obtained from all patients and healthy volunteers. Conflicts of interest: The authors declare no conflicts of interest.

References

    1. Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–54. https://doi.org/10.1016/j.jacc.2015.01.019 . - DOI - PubMed
    1. Abinader EG. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40(4):837–8. https://doi.org/10.1016/S0735-1097(02)02020-X . - DOI - PubMed
    1. Licordari R, Trimarchi G, Teresi L, et al. Cardiac magnetic resonance in HCM phenocopies: from diagnosis to risk stratification and therapeutic management. J Clin Med. 2023;12(10):3481. https://doi.org/10.3390/jcm12103481 . - DOI - PubMed - PMC
    1. Bick AG, Flannick J, Ito K, et al. Burden of rare sarcomere gene variants in the framingham and Jackson heart study cohorts. 2012;91(3):513–519. https://doi.org/10.1016/j.ajhg.2012.07.017.
    1. Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation. 2018;138(14):1387–98. https://doi.org/10.1161/CIRCULATIONAHA.117.033200 . - DOI - PubMed - PMC

LinkOut - more resources